These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 21672050)
1. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. La Rosa C; Limaye AP; Krishnan A; Blumstein G; Longmate J; Diamond DJ Transpl Int; 2011 Sep; 24(9):920-31. PubMed ID: 21672050 [TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection after liver transplantation: current concepts and challenges. Razonable RR World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591 [TBL] [Abstract][Full Text] [Related]
3. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269 [TBL] [Abstract][Full Text] [Related]
4. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis. Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605 [TBL] [Abstract][Full Text] [Related]
5. New developments in the management of cytomegalovirus infection after solid organ transplantation. Eid AJ; Razonable RR Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654 [TBL] [Abstract][Full Text] [Related]
6. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141 [TBL] [Abstract][Full Text] [Related]
8. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404 [TBL] [Abstract][Full Text] [Related]
13. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. Kalil AC; Freifeld AG; Lyden ER; Stoner JA PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751 [TBL] [Abstract][Full Text] [Related]
14. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651 [TBL] [Abstract][Full Text] [Related]
15. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. La Rosa C; Limaye AP; Krishnan A; Longmate J; Diamond DJ J Infect Dis; 2007 Mar; 195(5):633-44. PubMed ID: 17262704 [TBL] [Abstract][Full Text] [Related]
18. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
19. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644 [TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Gruber SA; Garnick J; Morawski K; Sillix DH; West MS; Granger DK; El-Amm JM; Alangaden GJ; Chandrasekar P; Haririan A Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]